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Background: Psoriasis vulgaris is a common chronic dermatological disease that has a negative impact on the psychological status and
the social interaction of the patient.
Objective: To correlate the quality of life and clinical severity of psoriasis vulgaris in patients using diﬀerent types of treatment.
Materials and methods: This is a prospective observational cross-sectional study that took place over a 4 month period, from January
to April 2014, at the King Abdul Aziz Medical City, Jeddah, Saudi Arabia. All patients with psoriasis vulgaris attending the dermatology
clinics during this period were included.
Results: Of the total 41 Saudi patients, 25 were males and 16 were females. 21 were on combined (i.e. topical with either systemic or
NB-UVB) and 20 were on topical treatments only. PASI score was moderate in the majority for both groups, that is, patients on topical
(70%) and combined treatment (80%). DLQI score shows only a small eﬀect on the patient’s quality of life for the majority (14/20) in the
topical group and (16/21) for those on combined therapy.
Conclusion: There is no signiﬁcant diﬀerence in terms of the eﬀect of the type of treatment between the two groups.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Psoriasis is a relatively common, chronic condition
aﬀecting between 1% and 3% of the general populationhttp://dx.doi.org/10.1016/j.jdds.2015.05.002
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Production and hosting by Elsevier(Grob and Folchetti, 1999; Koo, 1996; da Silva et al.,
2013). Classic psoriasis vulgaris usually appears in speciﬁc
areas including the elbows, knees and scalp. Although nei-
ther life threatening nor contagious, psoriasis causes mea-
surable harm to patient’s health-related quality of life
(HRQoL) through the psychological and social conse-
quences of having plaques on the skin (Ramsay and
O’Reagan, 1988).
Generally, a diagnosis of psoriasis is informed by exam-
ination of the skin. The classic symptoms of psoriasis
vulgaris are highly visible chronic erythematous plaques
covered by silvery white scales, forming on the elbows,
knees, scalp, umbilicus and lumbar area (Scho¨n andehalf of King Saud University.
commons.org/licenses/by-nc-nd/4.0/).
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(DLQI) is a10-item survey evaluating the quality of life
in patients with a skin disease, covering six domains: symp-
toms and feelings, daily activities, leisure, work and school,
Personal Relationships and treatment (Finlay and Khan,
1994). DLQI has-been found highly sensitive to improve-
ments in psoriasis symptoms and shows a positive correla-
tion with the psoriasis area severity index (PASI) (Basra
et al., 2008; Revicki et al., 2008). There are relatively few
studies in the literature examining the correlation between
quality of life and symptom severity in patients with
psoriasis (da Silva et al., 2013).
One study discusses the relationship between quality of
life and skin clearance in moderate-to-severe psoriasis
patients treated with inﬂiximab (Reich and Griﬃths,
2008). In Saudi Arabia, a study was done to evaluate the
quality of life in patients with psoriasis vulgaris before
and after phototherapy. This study concluded that narrow
band ultraviolet B (NB-UVB) photo therapy can improve
the quality of life in patients with psoriasis vulgaris (Al
Robaee and Alzolibani, 2011). To the best of our knowl-
edge, no prior study in our area compares quality of life
and clinical severity in patients using topical treatment
alone for psoriasis vulgaris with quality of life and clinical
severity in patients on combined treatment (that is, topical
treatment combined with either phototherapy or systemic)
to ﬁnd out if there is any correlation.2. Purpose of the study
To evaluate the quality of life and clinical severity of
psoriasis vulgaris in patients on topical and combined
treatment and compare the diﬀerences between the two
groups based on the type of the treatment.3. Methods and materials
A cross sectional survey was conducted between January
1st and April 30th, 2014 enrolling patients with psoriasis
vulgaris attending the Dermatology clinic at the King
Abdul Aziz medical city (KAMC). The (KAMC)
National Guard Hospital is a 540-bed referral healthcare
facility and teaching hospital. It is located in Jeddah and
serves all National Guard soldiers, employees and
dependents, as well as eligible patients in the western region
of Saudi Arabia. Data were collected from the patients by
dermatologists. A 10 item questionnaire using the veriﬁedTable 1
PASI score based on the type of the treatment.
PASI score result Topical treatment Com
Males Females Total Ma
Mild (1–10) 2 2 4 2
Moderate (10–20) 6 8 14 10
Severe (>20) 1 1 2 1
Total 9 11 20 13Arabic version of dermatology life quality index (DLQI)
was administered to the patients and an assessment of the
disease was carried out by using the psoriasis area severity
index (PASI). Patient data were documented on a special
form, including gender, age, BMI, smoking status and
detailed information about the type of treatment, dose, fre-
quency and duration of treatment. The study was approved
by King Abdullah International Medical Research Center
(KAIMRC), protocol number is RJ13/033/J.
The collecting data sheets of all patients visiting the der-
matology clinics during the study period were reviewed. No
inclusion or exclusion criteria were applied. A total of 41
papers were entered into the system. Data analysis was car-
ried out using SPSS v16.0 and descriptive statistics were
used to analyze the patient’s data.4. Results
A total of 41 patients with psoriasis vulgaris visited the
Dermatology clinic from January 2014 to April 2014. Of
these, 4 were newly diagnosed and 37 were known cases
coming in for follow-up. Of the 41 patients, 25 were males
and 16 were females, and all the patients were Saudi
nationals. The majority of the patients had been diagnosed
with psoriasis more than 10 years ago (23; 56.1%). Most of
those (31.71%) were having severe PASI score. Of the 41
patients, 21 were on combined treatment (topical with
either systemic or NB-UVB) and 20 were on topical treat-
ment only. The majority (11 out of 21 patients; 52.4%) of
those on combined treatment were on oral Methotrexate
with folic acid and topical calcipotriol with betamethasone
dipropionate ointment. The majority (17 out of 20 patients;
85%) of those on topical treatment were only on topical
calcipotriol with betamethasone dipropionate ointment.
PASI score was moderate in the majority of patients in
both groups, topical (14/20; 70%) and combined treatment
(17/21; 81%) (Table 1). Of the 41 patients, 17 (41.5%) had
nail changes in form of pitting and 9 (22%) had an estab-
lished diagnosis of psoriatic arthritis. The majority, 23
(56.1%), were obese and most of them (24.39%) had mild
PASI score. 19.5% were smokers in the study and the
majority of them 4 out of 8 (50%) were having severed
PASI score (Table 2). DLQI score shows only a small eﬀect
on the patient’s quality of life for the majority (14/20) of
patients in the topical group and a moderate eﬀect on the
patient’s quality of life for those on combined (16/21;
76.2%) (Table 3).bined treatment Total Percentage (%)
les Females Total
1 3 7 17.07
7 17 31 75.61
0 1 3 7.32
8 21 41 100.00
Table 2
PASI score with Chronicity, body mass index (BMI) and smoking status.
PASI score result Chronicity BMI Smokers
<5 years 5–10 years >10 years Normal (18–24) Over-weight (25–30) Obese (>30)
Mild (1–10) 2 1 4 5 4 10 3
Moderate (10–20) 3 3 6 3 0 6 1
Severe (>20) 4 5 13 2 4 7 4
Total 9 9 23 10 8 23 8
Table 3
DLQI score based on the type of the treatment.
DLQI score Topical treatment Combined treatment Total Percentage (%)
Males Females Total Males Females Total
No eﬀect at all on patient’s life 2 1 3 2 0 2 5 12.20
Small eﬀect on patient’s life 7 7 14 9 7 16 30 73.17
Moderate eﬀect on patient’s life 0 2 2 1 1 2 4 9.76
Very large eﬀect on patient’s life 0 1 1 1 0 1 2 4.88
Total 9 11 20 13 8 21 41 100.00
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The present study has produced evidence that psoriasis
has a meaningful negative impact on a patient’s QOL.
These results are consistent with previous researches on
psoriasis vulgaris (Choi and Koo, 2003; Fortune et al.,
1997; Finlay and Coles, 1995; Feldman et al., 1997). The
impact of the disease on patients’ QOL was principally
through emotional and psychological disability resulting
from the appearance of the plaques (Wahl et al., 2000;
Gupta and Gupta, 1997).
We found that quality of life was aﬀected more or less
equally by diﬀerent grades of psoriasis. No correlation
was found between the quality of life and clinical severity
of psoriasis vulgaris in patients using diﬀerent types of
treatment. It has always been thought by many dermatolo-
gists that patients on combined systemic therapy are
expected to have a better quality of life and less clinical
severity compared to those who are only on topical ther-
apy. However, in study sample we can conclude that there
is no statistical diﬀerence between the diﬀerent lines of the
treatment in terms of one being superior to the other in
giving the patient convenient quality of life and less clinical
severity.
6. Conclusions
We can conclude that treatment modality is not the
main factor in our study in determining the psoriatic
patient’s quality of life and clinical severity. However, we
can suggest that the absence of correlation in the present
study can be because of the Saudi Arabian traditional
dress, which covers most of the body for men and women,
limits social embarrassments from psoriasis and helps
patients cope with the appearance of the plaques on their
skin.Conﬂict of interest
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